Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
4상
완료
NCT05548647
| 대상 질환 | Obesity |
|---|
| 임상 단계 | 4상 |
|---|
| 스폰서 | University of Pennsylvania |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 120 명 |
|---|
| 중재(약물) | Behavioral Treatment, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] |
|---|
| 시작일 | 2022년 7월 26일 |
|---|
| 완료일 | 2025년 5월 12일 |
|---|
| 결과 공개일 | 2026년 8월 3일 |
|---|
요약
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)
S1: Change from baseline to weeks 20, 40, and 60 · kcal
| Behavioral Treatment + Placebo (Weeks 0-60) | -75.1 ± 52.6 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -367.0 ± 37.2 kcal |
|---|
| Behavioral Treatment + Placebo (Weeks 0-60) | -76.8 ± 73.8 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -317.0 ± 49.7 kcal |
|---|
| Behavioral Treatment + Placebo (Weeks 0-60) | 69.6 ± 73.9 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -200.0 ± 50.1 kcal |
|---|
| p-value | <0.0001 |
| Mean Difference (Net) | 291.9 (95% CI 164.0–419.8) |
Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)
S2: Endpoint comparison at week 72 · kcal
| Continuous Placebo (Weeks 60-72) | 1073.0 ± 71.1 kcal |
|---|
| Medication (Semaglutide) Switched to Placebo (Weeks 60-72) | 951.8 ± 42.9 kcal |
|---|
| Continued Medication (Semaglutide) (Weeks 60-72) | 657.7 ± 81.5 kcal |
|---|
| p-value | 0.1513 |
| Mean Difference (Final Values) | 121.2 (95% CI -46.0–288.4) |
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.